Novo Nordisk shares moved higher Tuesday after telehealth specialist Hims & Hers said that it would stop selling copycat versions of weight-loss drugs produced by the Danish company. Shares in the ...
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...
Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...
Around the world, progressive parties have come to see tight immigration restrictions as unnecessary, even cruel. What if ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Last year, the Vanguard S&P 500 Growth ETF ranked as the biggest winner among Vanguard's exchange-traded funds (ETFs). That's ...
The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug ...
Novo Nordisk A/S was the biggest leader among large stocks during the session, gaining 5.8%, and DNO ASA gained 5.4%. Carlsberg A/S Series A rounded out the top three leaders on Friday, with shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results